Head to head
Efruxifermin against Pegozafermin
The two FGF21 analogues furthest along in metabolic liver disease, both weekly or fortnightly injections, both in phase 3, and never compared with each other. Anyone following MASH drug development is choosing between trial records, not between products.
Column A
EfruxiferminEfruxifermin (EFX, AKR-001)
A weekly FGF21 analog that missed its 36-week primary endpoint in compensated MASH cirrhosis but improved fibrosis in 29% of patients by 96 weeks against 11% on placebo, with three Phase 3 SYNCHRONY trials under way.
Column B
PegozaferminPegozafermin (BIO89-100)
A glycoPEGylated FGF21 analog dosed weekly or every two weeks, now owned by Roche and in two Phase 3 MASH trials.
Side by side, on the facts we can check
| Attribute | Efruxifermin | Pegozafermin |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | Investigational; Phase 3 | Investigational; Phase 3 |
| Half-life | Weekly subcutaneous dosing | Weekly or every-two-week dosing |
| Molecular weight | 92,108 Da (Fc-FGF21 fusion protein) | No single molecular weight: a glycoPEGylated FGF21 analog whose PEG chain length varies (KEGG lists the protein plus an indefinite PEG term) |
| Mechanism | Long-acting FGF21 receptor agonism (FGFR1c/beta-klotho) that lowers liver fat, improves insulin sensitivity and reduces fibrosis. | Long-acting FGF21 analog acting on FGFR1c/beta-klotho to reduce liver fat and fibrosis and improve lipids. |
| Human studies cited | 2 | 2 |
| Legal status, US | Investigational, not approved | Investigational, not approved |
Frequently asked questions
What is the difference between Efruxifermin and Pegozafermin?
Efruxifermin: A weekly FGF21 analog that missed its 36-week primary endpoint in compensated MASH cirrhosis but improved fibrosis in 29% of patients by 96 weeks against 11% on placebo, with three Phase 3 SYNCHRONY trials under way. Pegozafermin: A glycoPEGylated FGF21 analog dosed weekly or every two weeks, now owned by Roche and in two Phase 3 MASH trials.
Which has stronger research evidence, Efruxifermin or Pegozafermin?
This database does not grade compounds. It counts what was run in people: 2 of the 2 studies cited on the Efruxifermin profile were human work, against 2 of 2 for Pegozafermin. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Efruxifermin and Pegozafermin FDA-approved?
Efruxifermin: Investigational; Phase 3. Pegozafermin: Investigational; Phase 3.
Related posts
Blog articles that cover Efruxifermin or Pegozafermin, newest first.
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.